Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.2252W HIGH $221.42
Volume
2.69 M
Value Traded
595.72 M
Short % Float
8.77%
+0.35%Week
+0.53%1 Month
+116.42%3 Month
+335.1%6 Month
+407.75%5 Year
-31.29%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.96 B
EPS (TTM)
-11.78
P/E Ratio
-
Ent. Value
6.54 B
Total Shares
31.42 M
Float Shares
21.46 M
Insiders
40.83%
Institutions
41.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CDTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Cidara Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How CDTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-20 | CD388 (antiviral influenza candidate) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$507M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Cidara Therapeutics, Inc. faces pipeline headwinds (36/100), with $780M risk-adjusted pipeline value, led by Rezafungin in Candidemia (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rezafungin Small moleculeCompletedNCT03667690 | Candidemia | Phase 3 | COMPLETED | 199 | Oct 7, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every CDTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Option | 1,286,786 4,652,309 held | $0.00 | 01/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CDTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.6 % (90 %) | 743.41 M | 3.37 M |
CDTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CDTX ranks across every disease it competes in
Competitive Position is a premium feature
See how CDTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCDTX News
About Cidara Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next CDTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime